Literature DB >> 30894316

Inhibition of Drp1 after traumatic brain injury provides brain protection and improves behavioral performance in rats.

Yan Song1, Tao Li2, Zhiguo Liu3, Zhenkuan Xu4, Zeli Zhang1, Lingyi Chi5, Yuguang Liu6.   

Abstract

The imbalance between mitochondrial fusion and fission has been implicated in cerebral ischemia and several neurodegenerative diseases. However, the role of mitochondrial fission in traumatic brain injury (TBI) remains poorly understood. Mitochondrial fission is mediated by dynamin-related protein 1 (Drp1), which is highly expressed in the nervous system. In the present study, we investigated the changes in Drp1 expression in the ipsilateral hippocampus of rats after TBI and the effects of Mdivi-1 (a selective inhibitor of Drp1) as a post-insult treatment for TBI. Our findings showed that the protein levels of Drp1 were increased at 6 h and peaked at 12 h post-TBI, but we did not observe Drp1 phosphorylation at Ser616, Ser637, Ser40 or Ser44 during this process. We examined the effect of Mdivi-1 on trauma-induced brain damage in both vitro and vivo. In cells, Mdivi-1 significantly attenuated H2O2-induced mitochondrial membrane potential (MMP) dissipation in PC-12 cells. Three days of Mdivi-1 treatment significantly reduced the cortical lesion volume, blood-brain barrier permeability, brain edema and oxidative stress. Mdivi-1 reduced activated caspase-3 release in the cortical border zone and hippocampal dentate gyrus three days after TBI. Furthermore, treatment with Mdivi-1 for 4 weeks rescued neurogenesis in DG and attenuated hippocampal atrophy. Regarding behavioral outcomes, Mdivi-1-treated TBI rats showed a significant improvement in water maze acquisition and retention compared with the saline-treated TBI rats. Moreover, Mdivi-1 treatment reduced anxiety-like behavior in an open-field test. Our results support the notion that Mdivi-1 provides brain protection and improves the behavioral performance in TBI rats.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; Brain protection; Drp1; Learning and memory; Mdivi-1; Traumatic brain injury

Mesh:

Substances:

Year:  2019        PMID: 30894316     DOI: 10.1016/j.cbi.2019.03.013

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  6 in total

1.  Drp1 is widely, yet heterogeneously, distributed in the mouse central nervous system.

Authors:  Ting-Ting Luo; Chun-Qiu Dai; Jia-Qi Wang; Zheng-Mei Wang; Yi Yang; Kun-Long Zhang; Fei-Fei Wu; Yan-Ling Yang; Ya-Yun Wang
Journal:  Mol Brain       Date:  2020-06-10       Impact factor: 4.041

Review 2.  Effects of Mdivi-1 on Neural Mitochondrial Dysfunction and Mitochondria-Mediated Apoptosis in Ischemia-Reperfusion Injury After Stroke: A Systematic Review of Preclinical Studies.

Authors:  Nguyen Thanh Nhu; Qing Li; Yijie Liu; Jian Xu; Shu-Yun Xiao; Shin-Da Lee
Journal:  Front Mol Neurosci       Date:  2021-12-24       Impact factor: 5.639

Review 3.  A Levee to the Flood: Pre-injury Neuroinflammation and Immune Stress Influence Traumatic Brain Injury Outcome.

Authors:  Samuel Houle; Olga N Kokiko-Cochran
Journal:  Front Aging Neurosci       Date:  2022-01-12       Impact factor: 5.750

Review 4.  Traumatic Brain Injury and Blood-Brain Barrier (BBB): Underlying Pathophysiological Mechanisms and the Influence of Cigarette Smoking as a Premorbid Condition.

Authors:  Farzane Sivandzade; Faleh Alqahtani; Luca Cucullo
Journal:  Int J Mol Sci       Date:  2020-04-14       Impact factor: 5.923

5.  Activated Drp1-mediated mitochondrial ROS influence the gut microbiome and intestinal barrier after hemorrhagic shock.

Authors:  Chenyang Duan; Lei Kuang; Xinming Xiang; Jie Zhang; Yu Zhu; Yue Wu; Qingguang Yan; Liangming Liu; Tao Li
Journal:  Aging (Albany NY)       Date:  2020-01-18       Impact factor: 5.682

Review 6.  Novel Synthetic and Natural Therapies for Traumatic Brain Injury.

Authors:  Denise Battaglini; Dorota Siwicka-Gieroba; Patricia Rm Rocco; Fernanda Ferreira Cruz; Pedro Leme Silva; Wojciech Dabrowski; Iole Brunetti; Nicolò Patroniti; Paolo Pelosi; Chiara Robba
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.